Business Context and Reporting Period
This Form 8-K was filed by Gemini Therapeutics, Inc. (not Disc Medicine, Inc.) on May 13, 2021. The filing serves to announce the company's financial results for the quarter ended March 31, 2021. The registrant is incorporated in Delaware and trades on The Nasdaq Global Market under the symbol GMTX.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) for the full details of the financial results but does not include the data within the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document solely acts as a notification that results for the quarter ended March 31, 2021, have been announced.
Guidance, Outlook, and Risks
The filing does not provide specific guidance, outlook, management commentary, or risk factors. It includes a standard disclaimer stating that the information in this Form 8-K and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Verify the correct company name is Gemini Therapeutics, Inc. (GMTX), as the input metadata incorrectly listed "Disc Medicine, Inc."
- Review Exhibit 99.1 (the attached press release) to obtain actual financial figures for the quarter ended March 31, 2021.
- Confirm the filing date of May 13, 2021, aligns with the company's earnings release schedule.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.